Abstract
Activating mutations of KIT and platelet-derived growth factor receptor α (PDGFRA) are known to be alternative and mutually exclusive genetic events in the development of gastrointestinal stromal tumors (GISTs). We examined the effect of the mutations of these two genes on the gene expression profile of 22 GISTs using the oligonucleotide microarray. Mutations of KIT and PDGFRA were found in 17 cases and three cases, respectively. The remaining two cases had no detectable mutations in either gene. The mutation status of KIT and PDGFRA was directly related to the expression levels of activated KIT and PDGFRA, and was also related to the different expression levels of activated proteins that play key roles in the downstream of the receptor tyrosine kinase III family. To evaluate the impact of mutation status and the importance of the type of mutation in gene expression and clinical features, microarray-derived data from 22 GISTs were interpreted using a principal component analysis (PCA). Three relevant principal component representing mutation of KIT, PDGFRA and chromosome 14q deletion were identified from the interpretation of the oligonucleotide microarray data with PCA. After supervised analysis, there was at least a two fold difference in expression between GISTs with KIT and PDGFRA mutation in 70 genes. Our findings demonstrate that mutations of KIT and PDGFRA affect differential activation and expression of some genes, and can be used for the molecular classification of GISTs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Allander SV, Nupponen NN, Ringne’r M, Hostetter G, Maher GW, Goldberger N, Chen Y, Carpten J, Elkahloun AG and Meltzer PS . (2001). Cancer Res., 61, 8624–8628.
Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH, Maki RG, Socci ND, DeMatteo RP and Besmer P . (2004). Clin. Cancer Res., 10, 3282–3290.
Barker SA, Caldwell KK, Pfeiffer JR and Wilson BS . (1998). Mol. Cell Biol., 9, 483–496.
Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L, Snyder HW, Broudeur D, Zuckerman EE and Hardy WD . (1986). Nature (Lond.)., 320, 415–421.
Blume-Jensen P and Hunter T . (2001). Nature, 411, 355–365.
Brizzi MF, Dentelli P, Rosso A, Yarden Y and Pegoraro L . (1999). J. Biol. Chem., 274, 16965–16972.
Burack WR and Sturgill TW . (1997). Biochemistry, 36, 5929–5933.
Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, Paik YK, Kim HO and Kim H . (2003). Cancer Res., 63, 2188–2193.
El-Rifai W, Sarlomo-Rikala M, Andersson LC, Miettinen M and Knuutila S . (1998). Ann. Chir. Gynaecol., 87, 287–290.
El-Rifai W, Sarlomo-Rikala M, Andersson LC, Miettinen M and Knuutila S . (2000). Genes Chromosomes Cancer, 27, 387–391.
Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH and Weiss SW . (2002). Hum. Pathol., 33, 459–465.
Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C, Joseph N, Singer S, Grifth DJ, Haley A, Town A, Demetri GD, Fletcher CD and Fletcher JA . (2003). Science, 299, 708–719.
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y and Kitamura Y . (1998). Science, 279, 577–580.
Hirota S, Isozaki K, Nishida T and Kitamura Y . (2000). J. Gastroenterol., 35 (Suppl12), 75–79.
Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y and Kitamura Y . (2003). Gastroenterology, 125, 660–667.
Ihle JN and Kerr IM . (1995). Trends Genet., 11, 69–74.
Joseph LD, Vishwanath RL and Patrick OB . (1997). Science, 278, 680–686.
Kim NG, Kim JJ, Ahn JY, Seong CM, Noh SH, Kim CB, Min JS and Kim H . (2000). Int. J. Cancer, 85, 633–638.
Kindblom LG, Remotti HE, Aldenborg F and Meis-Kindblom JM . (1998). Am. J. Pathol., 152, 1259–1269.
Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, Sugahara H, Mitsui H, Kanayama Y and Kitamura Y . (1995). Blood, 85, 790–798.
Lasota J, Jasinski M, Sarlomo-Rikala M and Miettinen M . (1999). Am. J. Pathol., 154, 53–60.
Lewin KJ, Riddel RH and Weinstein WM . (1992). Gastrointestinal Pathology: Mesenchymal Tumors. Lewin KJ, Riddel RH and Weinstein WM (eds). Ikaku-Sroin: Tokyo, pp. 284–341.
Lux ML, Rubin BP, Biase TL, Chen C-J, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CDM and Fletcher JA . (2000). Am. J. Pathol., 156, 791–795.
Ma Y, Cunningham ME, Wang X, Ghosh I, Regan L and Longley BJ . (1999). J. Biol. Chem., 274, 13399–13402.
Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A, Mori H, Matsuda Y, Wada S, Sodeyama H, Nakata S, Kawamura N, Hata S, Watanabe M, Iijima Y and Katsuyama T . (2001). Gastroenterology, 120, 210–215.
Miettinen M, Majidi M and Lasota J . (2002). Eur. J. Cancer, 38, S39–S51.
Mui AL . (1999). Cell. Mol. Life Sci., 55, 1547–1558.
Nakahara M, Isozaki K, Hirota S, Miyagawa J, Hase-Sawada N, Taniguchi M, Nishida T, Kanayama S, Kitamura Y, Shinomura Y and Matsuzawa Y . (1998). Gastroenterology, 115, 1090–1095.
Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, Zhu S, Fero M, Sherlock G, Pollack JR, Brown PO, Botstein D and Matt van de Rijn . (2002). Lancet, 359, 1301–1307.
Pawson T . (2002). Eur. J. Cancer, 38, S3–S10.
Porfiri E and McCormick F . (1996). J. Biol. Chem., 271, 5871–5877.
Raychaudhuri S, Stuart JM and Altman RB . (2000). Pac. Symp. Biocomput., 455–466.
Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen C-J, Xiao S, Tuveson DA, Demetri GD, Fletcher CD and Fletcher JA . (2001). Cancer Res., 61, 8118–8121.
Schindler C and Darnell JE . (1995). Annu. Rev. Biochem., 64, 621–651.
Schlessinger J . (2000). Cell, 103, 211–225.
Subramanian S, West RB, Corless CL, Ou W, Rubin BP, Chu K-M, Leung SY, Yuen ST, Zhu S, Hernandez-Boussard T, Montgomery K, Nielsen TO, Patel RM, Goldblum JR, Heinrich MC, Fletcher JA and van de Rijn M . (2004). Oncogene online published.
Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H and Kitamura Y . (1999). Cancer Res., 59, 4297–4300.
Timokhina I, Kissel H, Stella G and Besmer P . (1998). EMBO J., 17, 6250–6262.
Weiler SR, Mou S and DeBerry CS . (1996). Blood, 87, 3688–3693.
West RB, Corless CL, Rubin BP, Chen X, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Browm PO, Heinrich MC and van de Rijn M . (2004). Am. J. Pathol., 165, 107–113.
Zhang C, Schmidt M, von Eichei-Streiber C and Jakobs KH . (1996). Mol. Pharmacol., 50, 864–869.
Acknowledgements
We are grateful for Jung Jin Kim and Se Kyung Kim for technical assistance. This work has been supported by a grant from of the 2001 Korean National Cancer Program, the Cancer Metastasis Research Center at Yonsei University and Ministry of Health & Welfare, Republic of Korea, Ministry of Commerce Industry and Energy, Republic of Korea (MCIE-00008131).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc)
Rights and permissions
About this article
Cite this article
Kang, H., Nam, S., Kim, H. et al. Correlation of KIT and platelet-derived growth factor receptor α mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 24, 1066–1074 (2005). https://doi.org/10.1038/sj.onc.1208358
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208358
Keywords
This article is cited by
-
Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib
Cell & Bioscience (2020)
-
Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS)
Pathology & Oncology Research (2020)
-
miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT
Cell Communication and Signaling (2018)
-
Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor
Journal of Biosciences (2018)
-
Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors
Journal of Translational Medicine (2016)